Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 5:35 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 62 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: 1 mg Psilocybin Clear all

Conditions: Aging
Interventions: Psilocybin; Drug
Lead sponsor: University of California, Berkeley; Other
Eligibility: 60 Years to 85 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Berkeley, California

Conditions: Post-Traumatic Headache
Interventions: Placebo oral capsule, Low Dose Psilocybin, High Dose Psilocybin; Drug
Lead sponsor: Yale University; Other
Eligibility: 21 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: West Haven, Connecticut

Conditions: Obsessive-compulsive Disorder (OCD)
Interventions: Psilocybin 100 mcg/kg, Psilocybin 300 mcg/kg, Lorazepam 1 mg; Drug
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years to 65 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Phase I
Interventions: Psilocybin (Usona Institute), Inactive Placebo (Usona Institute); Drug
Lead sponsor: Brown University; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Amyotrophic Lateral Sclerosis
Interventions: Psilocybin; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Stuttering
Interventions: Psilocybin, Speech therapy; Drug · Behavioral
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 50 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Major Depressive Disorder
Interventions: No intervention will be administered as part of this study.; Other
Lead sponsor: Usona Institute; Other
Eligibility: 21 Years to 65 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Lauderhill, Florida

Conditions: Bipolar II Disorder, Depression, Bipolar, Suicidality
Interventions: Psilocybin, Therapeutic Support; Drug · Behavioral
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 25 Years to 70 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Hospice, Psilocybin, Demoralization, Terminal Illness, Cancer-related Problem/Condition, Psychotherapy, Terminal Cancer, Cancer Terminal
Interventions: Psilocybin, Psychotherapy; Drug · Behavioral
Lead sponsor: Yvan Beaussant, MD, MSci; Other
Eligibility: 21 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Danvers, Massachusetts

Conditions: Anorexia Nervosa
Interventions: Psilocybin; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 40 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Opioid Use Disorder
Interventions: Psilocybin; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 21 Years to 70 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: IBS - Irritable Bowel Syndrome
Interventions: Psilocybin 25 mg, Psychotherapy Treatment Session, Niacin 100 mg; Drug · Behavioral
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 75 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: QTc Interval, Pharmacokinetics
Interventions: Psilocybin, Moxifloxacin, Micro-Crystalline Cellulose; Drug
Lead sponsor: Usona Institute; Other
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Depressive Disorder, Major
Interventions: Psilocybin 25 mg, Inactive Placebo, Psilocybin 5 mg, Psychosocial Support; Drug · Behavioral
Lead sponsor: Usona Institute; Other
Eligibility: 18 Years and older
Enrollment: 238 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 29
States / cities: Birmingham, Alabama • Fayetteville, Arkansas • Little Rock, Arkansas + 25 more

Conditions: Healthy
Interventions: Psilocybin, Placebo; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Opioid Use Disorder
Interventions: Psilocybin (high dose), psilocybin (low dose); Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 60 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Well-Being, Psychological, Psychedelic Experiences
Interventions: Psilocybin, Saline Placebo, Clonidine; Drug · Other
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 45 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2027 – 2028
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Amblyopia
Interventions: Amblyopia Therapy, 1 mg Psilocybin, 5 mg Psilocybin, 10 mg Psilocybin, 15 mg Psilocybin, 20 mg Psilocybin, 25 mg Psilocybin; Behavioral · Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Fibromyalgia
Interventions: Psilocybin, Psychotherapy; Drug · Behavioral
Lead sponsor: Kevin Boehnke; Other
Eligibility: 25 Years to 64 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Opioid Use Disorder
Interventions: Psilocybin; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 21 Years to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2028
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Treatment Resistant Depression
Interventions: Psilocybin; Drug
Lead sponsor: COMPASS Pathways; Industry
Eligibility: 18 Years and older
Enrollment: 572 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 62
States / cities: Gilbert, Arizona • Bellflower, California • Encino, California + 50 more

Conditions: Early-stage Breast Cancer, Fear of Cancer Recurrence, Anxiety, Depression
Interventions: Psilocybin 25 mg, Psilocybin 5 mg; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 21 Years and older · Female only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2031
U.S. locations: 2
States / cities: Aurora, Colorado • New York, New York

Conditions: Methamphetamine Use Disorder
Interventions: Psilocybin (single oral capsule administered at one of two dose levels, Dose A or Dose B; specific doses withheld during conduct)., Manualized cognitive behavioral therapy platform (2 preparation + 2 integration sessions).; Drug · Behavioral
Lead sponsor: Peter Hendricks; Other
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2032
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Methamphetamine Use Disorder, Human Immunodeficiency Virus (HIV)
Interventions: Psilocybin 5 mg, Psilocybin 25 mg, Motivational Support; Drug · Behavioral
Lead sponsor: Nicky Mehtani, MD, MPH; Other
Eligibility: 25 Years to 64 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: San Francisco, California

Search by objective public record fields.

Investigating the Persisting Effects of a Single Dose of Psilocybin on Structural Plasticity in Healthy Older Adults

Effects of Psilocybin in Concussion Headache

Psilocybin for Treatment of Obsessive Compulsive Disorder

Pilot Study on the Effects of Psilocybin on Belief Updating and Insight Formation

Effects of Psilocybin in Patients With Amyotrophic Lateral Sclerosis

Effects of Psilocybin on Speech Fluency, Struggle, and Brain Activity in People Who Stutter

PSIL201 Long-term Follow-up Study: Psilocybin or Niacin / Major Depressive Disorder

Acceptability & Safety of Two Sequential Doses of Psilocybin in Bipolar Disorder II Depression and Suicidality

Pilot Study of Psilocybin-Assisted Therapy for Demoralization in Patients Receiving Hospice Care

Evaluation of Psilocybin in Anorexia Nervosa: Safety and Efficacy

Outpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder

Psilocybin-Assisted Psychotherapy in Treating Irritable Bowel Syndrome (IBS)

An Evaluation of Psilocybin's Effect on Cardiac Repolarization and the Effect of Food on Psilocybin's Pharmacokinetics

Psilocybin for Major Depressive Disorder (MDD)

Effects of Psilocybin on Electrophysiology and the Dynamic Content of Thought

Psilocybin on Brain Mechanisms of Motivation in OUD

Consciousness and Psilocybin Effects on Well-Being: The CoPEWell Study

Psilocybin for Amblyopia - Targeting Critical Periods in Humans

Open-label Study to Assess the Safety and Efficacy of Psilocybin With Psychotherapy in Adult Participants With Fibromyalgia

Inpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder

Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD

Psilocybin FCR Early-Stage Breast Cancer

Psilocybin for Methamphetamine Use Disorder

Psilocybin Therapy for Methamphetamine Use Disorder and HIV